Novocure
Highly Engaged Employees
Manufacturing · Switzerland · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Neuhofstrasse 21, Baar, Zug, 6340, Switz...Phone Number
+44 1534756700Website
www.novocure.comRevenue
$674.4 MillionStock Symbol
NVCRIndustry
About Novocure
Novocure Org Chart
Is Novocure your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Novocure
Check if Novocure has recently received funding, and reach out quickly before it becomes old news!
Check out if Novocure is spiking on competitors!
Website visits: Recent activity has been detected on your website
Novocure, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Novocure has new funding data
Earning: See what the market has to say on Novocure recently announced quarterly report
Click to see if Novocure had a recent Job posting/layoffs
Product Launch: Get notified when Novocure launches new products
Recommended Actions
Find VP level buyers at Novocure
Find 2 more new buyers
Company Profile Activity
Activity Insights
Novocure is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Novocure is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Novocure.
Novocure financials insights
Gather financial insights about Novocure, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Stock Offering
$158M
Debt
$150M
Debt
$400M
Novocure Tech Stack
A closer look at the technologies used by Novocure
Most Recent Scoops
Novocure News & Media
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?
AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)
Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday on June 18, 2026. NEW YORK,, June 18, 2026 /PRNewswire/ -- Investors who held Novocure...
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for... Read More

